JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB99815

Anti-Human IgG4 pFc’ [HP6023] (FITC)

Anti-Human IgG4 pFc’ [HP6023] (FITC)

Be the first to review this product! Submit a review

|

(2 Publications)

Suitable for Dot, ELISA, WB, ICC/IF. Cited in 2 publications.

別名を表示する

Immunoglobulin heavy constant gamma 4, Ig gamma-4 chain C region, IGHG4

関連する標識済み抗体及び組成の異なる製品 (4)

  • Unconjugated

    Anti-Human IgG4 pFc’ [HP6023]

  • Alkaline Phosphatase

    Anti-Human IgG4 pFc’ [HP6023] (Alkaline Phosphatase)

  • Biotin

    Anti-Human IgG4 pFc’ [HP6023] (Biotin)

  • 578 PE

    Anti-Human IgG4 pFc’ [HP6023] (PE)

Key facts

宿主種

Mouse

ターゲット種

Human

ターゲットアイソタイプ

IgG4

ターゲット特異性

Fc region

最小限の交差反応性
血清吸着処理済み

No

標識

FITC

励起波長/蛍光波長

Ex: 495nm, Em: 519nm

アプリケーション

Dot, ELISA, WB, ICC/IF

applications

クローン性

Monoclonal

クローン番号

HP6023

アイソタイプ

IgG3

軽鎖のタイプ

kappa

免疫原

Full Length Protein corresponding to Human IGHG4. The exact immunogen used to generate this antibody is proprietary information.

P01861

特異性

ab99815 reacts with the pFc’ portion of the heavy chain of Human IgG4.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "Dot": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p>(for Dot and slot immunoblotting)</p>" }, "ELISA": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "ICC/IF": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"1 µg for 10^6 Cells", "notes":"<p></p>" } } }

製品の詳細

Source: Ascites fluid

出荷温度及び保存条件

製品の状態
Liquid
精製方法
Affinity purification Protein A
バッファー組成
pH: 7.4 Preservative: 0.1% Sodium azide Constituents: PBS
出荷温度
Blue Ice
短期保存温度
+4°C
長期保存温度
+4°C
保管に関する情報
Store in the dark

製品プロトコール

ターゲットの情報

Constant region of immunoglobulin (Ig) heavy chains. Igs are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound Igs serve as receptors, which upon binding to a specific antigen trigger the clonal expansion and differentiation of B lymphocytes into Ig-secreting plasma cells. Secreted Igs known as antibodies mediate the effector phase of humoral immunity by blocking the interaction of infectious antigens with cellular receptors (via the antigen-binding region) and eliciting effector mechanisms that lead to pathogen neutralization (via the constant region) (PubMed : 17576170, PubMed : 20176268, PubMed : 22158414). The antigen-binding region is formed by the variable domain of one heavy chain paired with the variable domain of its associated light chain. Each Ig molecule has two antigen-binding sites with remarkable affinity for a particular antigen due to V-(D)-J rearrangement, somatic hypermutations and affinity maturation of the variable domains upon antigen exposure (PubMed : 17576170, PubMed : 20176268, PubMed : 22158414). The constant region defines the Ig isotype that perform distinct sets of effector functions. B cells diversify and rearrange their Ig constant regions through class-switch recombination, a process by which the constant region is switched from one Ig isotype to another, namely from IgM and IgD to IgG, IgA and IgE (PubMed : 17576170, PubMed : 20176268, PubMed : 22158414). The constant region interacts (via the fragment crystallizable, Fc) with the Fc receptors on innate immune cells to mediate humoral effector functions. Ig gamma-4 (IgG4) isotype does not elicit antibody-dependent cellular cytotoxicity (ADDC) or complement-dependent cytotoxicity (CDC). Instead it is likely involved in immune tolerance mechanisms to allergens and parasites either by blocking IgE-antigen complex formation or by directly inhibiting mast cell degranulation through Fc receptor signaling. In the context of tumorigenesis, it may participate in immunosuppressive mechanisms.
See full target information IGHG4

文献 (2)

Recent publications for all applications. Explore the full list and refine your search

Journal of neurology 271:2736-2744 PubMed38386048

2024

Different pain phenotypes are associated with anti-Caspr2 autoantibodies.

Applications

Unspecified application

Species

Unspecified reactive species

Patrik Greguletz,Maria Plötz,Carolin Baade-Büttner,Christian G Bien,Katharina Eisenhut,Christian Geis,Robert Handreka,Jaqueline Klausewitz,Peter Körtvelyessy,Stjepana Kovac,Andrea Kraft,Jan Lewerenz,Michael Malter,Michael Nagel,Felix von Podewils,Harald Prüß,Anna Rada,Johanna Rau,Sebastian Rauer,Rosa Rößling,Thomas Seifert-Held,Kai Siebenbrodt,Kurt-Wolfram Sühs,Simone C Tauber,Franziska Thaler,Judith Wagner,Jonathan Wickel,Frank Leypoldt,Heike L Rittner,Claudia Sommer,Carmen Villmann,Kathrin Doppler

The Journal of clinical investigation 132: PubMed35139037

2022

Streptococcus pneumoniae colonization associates with impaired adaptive immune responses against SARS-CoV-2.

Applications

Unspecified application

Species

Unspecified reactive species

Elena Mitsi,Jesús Reiné,Britta C Urban,Carla Solórzano,Elissavet Nikolaou,Angela D Hyder-Wright,Sherin Pojar,Ashleigh Howard,Lisa Hitchins,Sharon Glynn,Madlen C Farrar,Konstantinos Liatsikos,Andrea M Collins,Naomi F Walker,Helen C Hill,Esther L German,Katerina S Cheliotis,Rachel L Byrne,Christopher T Williams,Ana I Cubas-Atienzar,Tom E Fletcher,Emily R Adams,Simon J Draper,David Pulido,Rohini Beavon,Christian Theilacker,Elizabeth Begier,Luis Jodar,Bradford D Gessner,Daniela M Ferreira
View all publications

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com